Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

18th European Diabetes Congress

Lisbon, Portugal

P R Raghavan

P R Raghavan

Nanorx Inc., USA

Title: Metadichol® a novel nano lipid emulsion; gpr120 agonist against insulin resistance

Biography

Biography: P R Raghavan

Abstract

Metadichol (US patent 8,722,093) is a nano emulsion of long-chain alcohols found in many foods. It is commonly called policosanol and is present in foods such as rice, sugar cane, wheat and peanuts. Metadichol acts on nuclear vitamin D receptors (VDR) (US patent 9,006,292) that are present in cells throughout the body to stimulate the immune system and inhibit a variety of disease processes. Vitamin D deficiency has been shown to alter insulin synthesis and secretion in both humans and animal models. Downfield effects of VDR lead to GPR 120 agonist activity with an EC50 of 3.3 ug/ml when compared with the known agonist GW9508. The anti-inflammatory effect of GPR120 stimulation promotes insulin sensitivity. Metadichol® treatment of ZDF rats showed a reduction of fasting glucose levels and decreased insulin resistance. Also, we have demonstrated that it increases insulin production and also reduces insulin in cases of hyperinsulinemia. Case studies of type 1 and type 2 diabetes and gene expression analysis will also be presented. Anti-diabetic activity of Metadichol® in ZDF rats showed reduction in fasting glucose levels and decreased insulin resistance. In addition, it increases insulin production and also reduces insulin in cases of hyperinsulinemia. Case studies of type 1, type 2 diabetes and gene expression analysis will also be presented. Metadichol consists of natural components of common foods and has no known negative side effects; Metadichol has the potential to serve as a novel, treatment for insulin related diseases. It has the potential to serve as a novel treatment for diabetes related diseases that confront public health today.